Holen Sie sich die Stockscreener-App
1.15
4.96%
-0.06
Handel nachbörslich:
1.15
Schlusskurs vom Vortag:
$1.21
Offen:
$1.16
24-Stunden-Volumen:
178.60K
Relative Volume:
0.51
Marktkapitalisierung:
$77.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.20M
KGV:
-0.5349
EPS:
-2.15
Netto-Cashflow:
$57,000
1W Leistung:
-9.45%
1M Leistung:
-14.81%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.11
$1.22
1-Wochen-Bereich:
$1.11
$1.33
52-Wochen-Spanne:
$1.11
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Vergleichen Sie CLYM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
1.15 | 77.60M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
CLYM stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
Climb Bio expands board with two new directors By Investing.com - Investing.com Australia
Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board - TipRanks
Climb Bio expands board with two new directors - Investing.com
Climb Bio Expands Board with New Director Appointments - TipRanks
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times
Biotech Leaders Join Climb Bio Board: 11 Successful Drug Launches Experience - Stock Titan
CLYM stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa
What is Leerink Partnrs’ Estimate for Climb Bio Q2 Earnings? - Defense World
Bioplastics And Biopolymers Market Key Drivers, Opportunities and Trends | Exactitude Consultancy - Yahoo Finance
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Healthcare Spotlight: Climb Bio Takes Center Stage at Major Needham Conference - Stock Titan
Climb Bio Advances Clinical Trials and Expands Pipeline - TipRanks
Can you use home equity to pay for long-term care? - Yahoo Finance
Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report - Yahoo Finance
Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Downloadable Quarterly Update - Yahoo Finance
Citigroup (C) Could Be a Great Choice - Yahoo Finance
China deals look beyond cancer - BioCentury
Climb Bio Files For Offering Of Common Stock Up To $22.4 MillionSEC Filing - MarketScreener
Climb Bio Reports Fourth Quarter And Year-End 2024 Financial Results And Provides Business Updates - Marketscreener.com
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates - Yahoo
Conagra to close Michigan plant, impacting 85 jobs - Yahoo Finance
Exclusive: BlackRock expands blockchain-based money market to Solana, in tie-up with startup Securitize - Yahoo Finance
Climb Bio Secures 3-Year Cash Runway with $212M, Advances Multi-Disease Pipeline - Stock Titan
Climb bio SVP Emily Pimblett sells shares worth $1,570 By Investing.com - Investing.com South Africa
Climb bio SVP Emily Pimblett sells shares worth $1,570 - Investing.com India
Why Are Jabil (JBL) Shares Soaring Today - Yahoo Finance
Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report - Yahoo Finance
Climb Bio (CLYM) Expected to Announce Earnings on Thursday - Defense World
Gossamer Bio shares rise on Q4 earnings beat By Investing.com - Investing.com South Africa
Gossamer Bio shares rise on Q4 earnings beat - Investing.com India
Bio-Key International Inc (BKYI): Major Improvements, Worth A Look - Stocks Register
Sugar Prices Climb on the Prospects for Lower Global Sugar Production - The Globe and Mail
Sugar Prices Climb on the Outlook for Small Sugar Output in India - The Globe and Mail
CLYM stock touches 52-week low at $1.29 amid market challenges - Investing.com Australia
CLYM stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa
(PDF) Research on Dynamics and Stability in the Stairs-Climbing of a Tracked Mobile Robot - ResearchGate
Stocks of Codexis Inc (CDXS) are poised to climb above their peers - SETE News
Mineralys shares climb on study data for blood pressure drug - BioPharma Dive
First-class stamp price climbs to £1.70 in ‘blow to consumers’ - Yahoo Finance UK
Global stocks climb as pound and euro hit four-month high against US dollar - Yahoo Finance UK
Climb Bio (NASDAQ:CLYM) Shares Down 6.9% – Should You Sell? - Defense World
FTSE 100 and US stocks climb higher as US inflation report meets expectations - Yahoo Finance UK
Stocks Climb Ahead Of Nvidia's Earnings Results - Barchart
Coupang’s shares climb after profit surges in competitive market - Fortune
CLYM stock touches 52-week low at $1.4 amid market challenges - Investing.com Australia
CLYM stock touches 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Plug To Announce 2024 Fourth Quarter and Year-End Results - The Manila Times
Climb Bio to Present at Upcoming Investor Conferences - The Bakersfield Californian
Climb Bio Sets Investor Calendar: Key March Presentations at Major Healthcare Conferences - StockTitan
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):